The IPO market came back full force this week following the July 4th pause. Nine deals raised a combined $931 million, averaging a gain of 29%. Five biotechs went public, including top performer Allakos, which finished the week up 95%. Tilray grabbed...read more
Constellation Pharmaceuticals, which is developing epigenetic cancer therapies that modulate abnormal genes, raised $60 million in a downsized offering of 4.0 million shares at $15, the midpoint of the $14 to $16 range. It originally filed to raise $80 million...read more
There are 10 IPOs expected to price this week after the July holiday slowdown. The week is being led by oil and gas OEM AFG Holdings and Canadian cannabis supplier Tilray. Six...read more
Constellation Pharmaceuticals, which is developing epigenetic cancer therapies that modulate abnormal genes, announced terms for its IPO on Monday.
The Cambridge, MA-based company plans to raise $80 million by offering 5.3 million shares at a price range of...read more
US IPO Weekly Recap: Bud, biotechs, banks and breast implants make gains in 9-IPO week
The IPO market came back full force this week following the July 4th pause. Nine deals raised a combined $931 million, averaging a gain of 29%. Five biotechs went public, including top performer Allakos, which finished the week up 95%. Tilray grabbed...read more
Cancer biotech Constellation Pharmaceuticals prices downsized IPO at $15 midpoint
Constellation Pharmaceuticals, which is developing epigenetic cancer therapies that modulate abnormal genes, raised $60 million in a downsized offering of 4.0 million shares at $15, the midpoint of the $14 to $16 range. It originally filed to raise $80 million...read more
US IPO Week Ahead: 10 US IPOs planned for the week of July 16
There are 10 IPOs expected to price this week after the July holiday slowdown. The week is being led by oil and gas OEM AFG Holdings and Canadian cannabis supplier Tilray. Six...read more
Cancer biotech Constellation Pharma sets terms for $80 million IPO
Constellation Pharmaceuticals, which is developing epigenetic cancer therapies that modulate abnormal genes, announced terms for its IPO on Monday. The Cambridge, MA-based company plans to raise $80 million by offering 5.3 million shares at a price range of...read more